Table 4.
Comparison of survival and progression-free survival between the two groups
Follow-up results
|
S-1 group (n = 47)
|
Gemcitabine group (n = 47)
|
t
|
P
value
|
Progress-free survival (mo) | 6.63 (1.02) | 6.25 (0.94) | 1.878 | 0.064 |
Survival (mo) | 13.63 (1.52) | 13.02 (1.45) | 1.991 | 0.050 |